Clinical Trials Browser

Breast Neoplasms × dostarlimab × 1 year × Clear all

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04584255 2026-05-13

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Phase 2 Active not recruiting

62 enrolled

Breast

Breast Neoplasms

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1 Active not recruiting

18 enrolled

BreastGastrointestinalGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT04837209 2025-10-01

NADiR

Phase 2 Active not recruiting

32 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

I-SPY

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

NADiR